Medicare GLP-1 Bridge: $50/month eligibility and Part D cost rules

ByBrian “Weence” Bateman

Starting July 1, 2026, Medicare begins a temporary “GLP-1 Bridge” for some people with Medicare Part D. Eligible beneficiaries can get certain weight-loss GLP-1 drugs for a predictable $50 copay per month through Dec. 31, 2027—through a pathway that doesn’t work like standard Part D cost-sharing (including how TrOOP, deductibles, and low-income subsidy work).

Starting July 1, 2026, Medicare begins a temporary program called the Medicare GLP-1 Bridge to help some Medicare Part D enrollees pay for certain GLP-1 weight-loss medicines for a $50 copay per month. The Bridge runs through Dec. 31, 2027.

Because the Bridge operates outside the usual Part D coverage and payment flow, the $50 copay does not behave like standard Part D spending—especially for deductibles, TrOOP, and low-income subsidy (LIS) rules.

What the Medicare GLP-1 Bridge is

CMS describes the Medicare GLP-1 Bridge as a short-term demonstration that provides eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026 and Dec. 31, 2027. CMS also says the Bridge will operate outside the Part D benefit’s coverage and payment flow.

Which medicines are included

Medicare.gov’s Bridge fact sheet lists these covered drugs:

  • Foundayo (tablet)
  • Wegovy (injection or tablet)
  • Zepbound (KwikPen only)

The fact sheet also specifies that the single-dose Zepbound pen and Zepbound vials are NOT covered under this Bridge.

Who qualifies for the $50/month copay

Medicare.gov says you generally must meet all four requirements below:

  • You have Medicare Part D drug coverage—either a standalone Medicare Drug Plan, or a Medicare health plan that includes drug coverage.
  • Your coverage type matters: you’re not eligible if your only Medicare coverage is through certain special plan types (for example, private fee-for-service plans, cost contract plans, or a PACE organization).
  • You can’t be getting a GLP-1 through your Medicare drug plan:

    • You’re not eligible to receive a GLP-1 drug through your Medicare drug plan under this Bridge.
    • If you’ve already been using a GLP-1 that’s been paid for by your Medicare drug plan for any reason, you generally need to keep getting your GLP-1 through your plan.
    • The fact sheet also notes that GLP-1 drugs are defined by certain active ingredients (including semaglutide, tirzepatide, orforglipron, dulaglutide, and liraglutide).
  • You meet clinical criteria:

    • You don’t have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease (if you have any of these, Medicare.gov directs you to contact your Medicare drug plan because it may already cover a GLP-1 for you).
    • You’re at least 18 years old and meet at least one BMI-based threshold:
      • BMI 35+, or
      • BMI 30+ plus certain heart failure or hard-to-control high blood pressure, or chronic kidney disease stage 3a or above, or
      • BMI 27+ plus prediabetes or a history of heart attack, stroke, or blocked arteries in your legs or arms.

How coverage works (the approval process)

The Bridge has steps that involve your clinician and pharmacy. Medicare.gov’s fact sheet describes this general flow:

  1. Talk with your doctor about whether a GLP-1 drug is right for you and whether you qualify for the program.
  2. If a covered drug is appropriate, your doctor sends a prescription to the pharmacy.
  3. Your pharmacy may reach out for your Medicare ID number (printed on your card). If you don’t have your card, the pharmacist can look up your number using the last four digits of your Social Security Number.
  4. After the pharmacy confirms you are eligible for Medicare GLP-1 Bridge, your doctor needs to submit a form to get approval from Medicare for coverage.
  5. You’ll receive a letter from Medicare letting you know your medicine is covered.

For refills, Medicare.gov says you typically don’t need a new approval as long as you stay on the same drug—even if your dose changes.

If you switch to a different covered GLP-1 drug, ask your clinician and pharmacy whether you’ll need the Bridge approval workflow again.

Why the $50 copay is different from standard Part D cost-sharing

CMS says the Bridge is provided outside of the Part D benefit payment flow and coverage. That’s why:

  • The Part D deductible does not apply.
  • No part of the $50 copay counts toward TrOOP (the standard drug plan out-of-pocket track used for coverage phases).
  • No low-income subsidy (LIS) is provided for LIS beneficiaries under the Bridge.
  • The fact sheet also says the $50 payment doesn’t count toward your Medicare drug plan deductible or your yearly out-of-pocket limit.
  • Medicare.gov says these Bridge drugs aren’t eligible for the Medicare Prescription Payment Plan.

Plain-language takeaway: you can expect $50/month for Bridge-covered refills, but you shouldn’t assume that spending will “flow into” the same Part D deductible or out-of-pocket limits you see on plan statements.

What may affect access, including in rural areas

Even when the program exists, getting the prescription filled can depend on practical steps like prescription processing and documentation. If you live in an area with fewer specialists or pharmacies, it can help to confirm early that your pharmacy can run the Medicare GLP-1 Bridge process and that your clinician’s office is set up to submit the required Medicare form.

When the Bridge ends (and what isn’t guaranteed)

CMS says the Medicare GLP-1 Bridge runs through Dec. 31, 2027. After that date, future access and affordability aren’t something Medicare can guarantee from current Bridge rules alone—so it’s reasonable to plan for the possibility that coverage terms could change if the program is not extended or if rules change.

Medication safety basics to discuss with a clinician

Overweight and obesity can affect health, and weight-loss medications can be part of a broader plan. The ADA notes that common side effects of obesity medications can include nausea, diarrhea, vomiting, constipation, or fatigue.

The ADA also says to seek help right away if symptoms become severe or include severe dizziness, severe vomiting, severe diarrhea, fainting, or an irregular heartbeat.

Reasonable next step: if you’re exploring Bridge eligibility, ask your clinician how the medication fits your overall plan (including monitoring and side-effect prevention) and what signs should prompt urgent care.

Key sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.

Related

Brian “Weence” Bateman is a health and medical writer who covers public health updates, healthcare policy, and medical developments affecting communities across the United States. He works closely with dentists and healthcare providers and focuses on making complex medical information clear, accurate, and useful for everyday readers.